Heart Failure Staging and Intervention

Definition and Rationale

The American College of Cardiology/American Heart Association staging system was designed to identify patients earlier in the disease continuum, with Stage B representing a distinct disease stage requiring specific interventions to prevent progression and reduce mortality 1, 2, 3, 4
Stage B patients have objective structural heart disease without symptoms, representing a critical threshold for intervention 1, 2, 3
The American College of Cardiology emphasizes that patients with structural abnormality are at a point of no return, unless progression of the disease is slowed or stopped by treatment 1, 5, 6

The American College of Cardiology recommends ACE inhibitors with Class I, Level A evidence for preventing symptomatic heart failure and reducing mortality in Stage B patients with left ventricular ejection fraction ≤40% 7
Beta blockers have Class I, Level B-R evidence for preventing symptomatic heart failure in Stage B patients 7
Statins reduce cardiovascular events and prevent progression in post-myocardial infarction patients 7, 8
Implantable cardioverter-defibrillators are indicated for Stage B patients ≥40 days post-myocardial infarction with left ventricular ejection fraction ≤30% and New York Heart Association class I symptoms for primary prevention of sudden cardiac death 7

The American College of Cardiology acknowledges that heart failure is defined as a clinical syndrome characterized by specific symptoms and signs, but also emphasizes that it is not equivalent to cardiomyopathy or left ventricular dysfunction 5, 9
The staging system intentionally captures the disease process before the syndrome manifests, which is the entire therapeutic opportunity 1, 6
The American College of Cardiology staging system was designed to be similar to staging or risk assessment systems for other disorders, such as cancer 1, 5, 6

The American College of Cardiology/American Heart Association staging system defines Stage C heart failure as patients with current or past symptoms of heart failure associated with underlying structural heart disease, encompassing NYHA functional classes I-IV 10
Stage C is defined by symptom history, not current symptom severity, and any patient who has ever experienced heart failure symptoms with structural heart disease is permanently classified as Stage C, regardless of treatment 10

The NYHA functional classification reflects current functional status and changes frequently in response to therapy or disease progression, while ACC/AHA stage progression is essentially unidirectional 10
NYHA Class I (Stage C) patients have prior heart failure symptoms but are now asymptomatic on treatment, with no limitation of physical activity 11, 12
NYHA Class II (Stage C) patients have slight limitation of physical activity, being comfortable at rest but experiencing fatigue, palpitation, or dyspnea with ordinary activity 11, 13
NYHA Class III (Stage C) patients have marked limitation of physical activity, being comfortable at rest but experiencing symptoms with less than ordinary activity 11, 13
NYHA Class IV (Stage C) patients are unable to carry on any physical activity without discomfort, with symptoms present even at rest 11, 13

Stage C represents the bulk of patients with heart failure in clinical practice, distinguishing them from Stage B and Stage D 10
The staging system is designed so patients cannot regress from Stage C back to Stage B, as having once developed the clinical syndrome of heart failure represents a permanent disease milestone 10